Navigation Links
NIH expands national consortium dedicated to transforming clinical and translational research
Date:5/29/2008

Fourteen academic health centers in 11 states are the latest members of the National Institutes of Healths Clinical and Translational Science Award (CTSA) consortium. Creating a unique network of medical research institutions across the nation, the consortium is working to reduce the time it takes for laboratory discoveries to become treatments for patients and to engage communities in clinical research efforts. It also is fulfilling the critical need to train the next generation of clinical and translational researchers. The consortium is led by the National Center for Research Resources (NCRR), a part of the NIH.

With more than half of NIHs funding allocated for basic research, the CTSA consortium is perfectly poised to help move discoveries in the laboratory to improved patient care. The consortium serves as the bridge in this process that allows researchers to perfect and refine existing treatments through interdisciplinary teams that extend to the clinic and community, said NIH Director Elias A. Zerhouni, M.D. Through the consortium, we are better able to leverage expertise and resources across the CTSA institutions, and ultimately maximize NIHs investment in basic research, which should remain a top priority.

The institutions receiving new CTSA funding include (*view descriptions of the CTSA awardees at www.ncrr.nih.gov/ctsa2008):

Albert Einstein College of Medicine of Yeshiva University (New York City)

Boston University (Boston)

Harvard University (Cambridge, Mass.)

Indiana University School of Medicine (Indianapolis)

Northwestern University (Chicago and Evanston, Ill.)

The Ohio State University (Columbus, Ohio)

The Scripps Research Institute (La Jolla, Calif.)

Stanford University (Palo Alto, Calif.)

Tufts University (Boston)

The University of Alabama at Birmingham (Birmingham, Ala.)

University of Colorado Denver (Aurora, Colo.)

The University of North Carolina at Chapel Hill (Chapel Hill, N.C.)

The University of Texas Health Science Center at San Antonio (San Antonio)

The University of Utah (Salt Lake City)

These 14 academic health centers join 24 others announced in 2006 and 2007. Total funding for these new awards is $533 million over five years. The 2008 CTSA grants expand state representation in the consortium to Alabama, Colorado, Indiana, Massachusetts, and Utah. They also support pediatric research at 13 dedicated childrens hospitals; expand research in genetics and genomics; enhance research in behavioral immunology and infection risk; and increase outreach into local communities.

As the CTSA consortium expands across the nation, the NIH is elevating clinical and translational research from a single research enterprise to a network of exceptional collaborations that will translate new knowledge into tangible benefits for the American people by bringing together diverse perspectives and expertise leading to new prevention strategies and clinical treatments, said NCRR Director Barbara M. Alving, M.D.

Since its launch in 2006, the consortium has been:

  • training researchers in the complexities of clinical and translational research through nationally recognized degree-granting programs;

  • leveraging CTSA resources to expand research and training opportunities in underserved states and communities;

  • assembling interdisciplinary teams that include but are not limited to basic scientists, biologists, clinical researchers, dentists, veterinarians, nurses, pharmacists, biomedical engineers, and geneticists;

  • partnering with researchers at minority institutions to enhance outreach to underserved populations, local community and advocacy organizations, and health care providers;

  • creating best practices to improve clinical research informatics tools to analyze research data and manage clinical trials;

  • designating technologies for marketing and licensing purposes that will increase global access to research tools; and

  • forging new partnerships with private and public health care organizations, including pharmaceutical companies, the Veterans Administration hospitals, health maintenance organizations, as well as state health agencies.

The CTSA initiative grew out of the NIH commitment to re-engineer the clinical research enterprise, one of the key objectives of the NIH Roadmap for Medical Research. Most of the funding will come from terminating grants to General Clinical Research Centers, supplemented by NIH Roadmap funds. In 2012, when the program is fully implemented, approximately 60 CTSAs will be connected with an annual budget of $500 million.

A fourth funding opportunity announcement for CTSAs is available, calling for the next round of applications to be submitted by June 17, 2008, with the awards expected in March 2009. More information about this funding announcement can be found at www.ncrr.nih.gov/crfunding. For more information about the CTSA program, visit www.ncrr.nih.gov/crctsa.


'/>"/>

Contact: Joyce McDonald
Info@ncrr.nih.gov
301-435-0888
NIH/National Center for Research Resources
Source:Eurekalert

Related biology news :

1. Ossur -- leading orthopedic pioneer - expands network to Asia
2. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
3. DHS Expands Biometrics-at-Sea Program to the Florida Straits
4. Springer expands publishing partnership with the Biomedical Engineering Society
5. Science expands Science Signaling, featuring research related to medical advances, and more
6. bioMETRX Expands Engineering and Manufacturing Capabilities
7. Wolves find happy hunting grounds in Yellowstone National Park
8. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
9. ESMO International Symposium on Immunology
10. Story tips from the US Department of Energys Oak Ridge National Laboratory, September 2007
11. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: